FYBD Stock Overview
A biotechnology company, develops biosimilar drugs in Germany and Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Formycon AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €63.30 |
| 52 Week High | €76.30 |
| 52 Week Low | €63.30 |
| Beta | 0.92 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -11.10% |
| 33 Year Change | 113.13% |
| 5 Year Change | 105.85% |
| Change since IPO | 97.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| FYBD | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 2.2% |
| 1Y | -11.1% | -18.3% | 8.0% |
Return vs Industry: FYBD exceeded the UK Biotechs industry which returned -28.7% over the past year.
Return vs Market: FYBD underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| FYBD volatility | |
|---|---|
| FYBD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: FYBD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FYBD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 224 | Stefan Glombitza | www.formycon.com |
Formycon AG develops and markets biosimilar products in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization under the Ranivisio, ONGAVIA, and CIMERLI names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of chronic inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea, that treats neovascular age-related macular degeneration and serious retinal diseases that is in Phase III clinical trials.
Formycon AG Fundamentals Summary
| FYBD fundamental statistics | |
|---|---|
| Market cap | €911.00m |
| Earnings (TTM) | -€42.23m |
| Revenue (TTM) | €68.64m |
13.3x
P/S Ratio-21.6x
P/E RatioIs FYBD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FYBD income statement (TTM) | |
|---|---|
| Revenue | €68.64m |
| Cost of Revenue | €44.26m |
| Gross Profit | €24.38m |
| Other Expenses | €66.62m |
| Earnings | -€42.23m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.63 |
| Gross Margin | 35.52% |
| Net Profit Margin | -61.53% |
| Debt/Equity Ratio | 0% |
How did FYBD perform over the long term?
See historical performance and comparison